These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. Yang C; Li YL; Fang J; Zhang X; Liu HP; Qin XH; Xu XP Zhonghua Nan Ke Xue; 2009 May; 15(5):441-4. PubMed ID: 19514558 [TBL] [Abstract][Full Text] [Related]
25. alpha 1-antagonists in the treatment of hypertension. Grimm RH Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457 [TBL] [Abstract][Full Text] [Related]
26. Antihypertensive therapy and the risk of coronary heart disease. Ames RP; Hill P J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S206-12. PubMed ID: 6177958 [TBL] [Abstract][Full Text] [Related]
27. The effects of terazosin and methyclothiazide on blood pressure and serum lipids. Luther RR; Glassman HN; Estep CB; Maurath CJ; Jordan DC Am Heart J; 1989 Apr; 117(4):842-7. PubMed ID: 2564723 [TBL] [Abstract][Full Text] [Related]
32. [Are all antihypertensive drugs renoprotective?]. Wolf S; Risler T Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950 [TBL] [Abstract][Full Text] [Related]
33. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Lowe FC; Olson PJ; Padley RJ Urology; 1999 Jul; 54(1):81-5. PubMed ID: 10414731 [TBL] [Abstract][Full Text] [Related]
34. Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs. Sharma R; Ahuja VM; Fahim M Indian J Exp Biol; 2004 Dec; 42(12):1195-9. PubMed ID: 15623230 [TBL] [Abstract][Full Text] [Related]
35. Implications of doxazosin therapy on risk of coronary heart disease. Hansson L Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759 [TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists. Reid JL; Vincent J Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958 [TBL] [Abstract][Full Text] [Related]
37. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Titmarsh S; Monk JP Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169 [TBL] [Abstract][Full Text] [Related]
38. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension. Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796 [TBL] [Abstract][Full Text] [Related]
40. [The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats]. Wang W Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):234-5. PubMed ID: 7910793 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]